Alto Neuroscience Inc. (NYSE: ANRO)’s stock price has gone rise by 1.68 in comparison to its previous close of 14.29, however, the company has experienced a 2.61% increase in its stock price over the last five trading days. businesswire.com reported 2024-10-22 that MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo. The favorable safety and tolerabili.
Is It Worth Investing in Alto Neuroscience Inc. (NYSE: ANRO) Right Now?
Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ANRO is 22.18M, and currently, shorts hold a 18.56% of that float. The average trading volume for ANRO on October 23, 2024 was 339.86K shares.
ANRO’s Market Performance
ANRO’s stock has seen a 2.61% increase for the week, with a 9.33% rise in the past month and a -1.62% fall in the past quarter. The volatility ratio for the week is 5.68%, and the volatility levels for the past 30 days are at 6.95% for Alto Neuroscience Inc. The simple moving average for the last 20 days is 17.14% for ANRO’s stock, with a simple moving average of 9.53% for the last 200 days.
Analysts’ Opinion of ANRO
Many brokerage firms have already submitted their reports for ANRO stocks, with Wedbush repeating the rating for ANRO by listing it as a “Outperform.” The predicted price for ANRO in the upcoming period, according to Wedbush is $29 based on the research report published on September 03, 2024 of the current year 2024.
ANRO Trading at 18.61% from the 50-Day Moving Average
After a stumble in the market that brought ANRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.46% of loss for the given period.
Volatility was left at 6.95%, however, over the last 30 days, the volatility rate increased by 5.68%, as shares surge +22.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +76.76% upper at present.
During the last 5 trading sessions, ANRO rose by +2.61%, in comparison to the 20-day moving average, which settled at $12.40. In addition, Alto Neuroscience Inc. saw -29.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANRO starting from Savitz Adam, who purchase 12,069 shares at the price of $12.60 back on Jul 09 ’24. After this action, Savitz Adam now owns 36,920 shares of Alto Neuroscience Inc., valued at $152,085 using the latest closing price.
Savitz Adam, the CHIEF MEDICAL OFFICER of Alto Neuroscience Inc., purchase 2,931 shares at $13.22 during a trade that took place back on Jul 10 ’24, which means that Savitz Adam is holding 39,851 shares at $38,748 based on the most recent closing price.
Stock Fundamentals for ANRO
Current profitability levels for the company are sitting at:
- -145.73 for the present operating margin
- 0.22 for the gross margin
The net margin for Alto Neuroscience Inc. stands at -133.88. The total capital return value is set at -0.29.
Based on Alto Neuroscience Inc. (ANRO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -4.17. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -38.39.
Currently, EBITDA for the company is -37.44 million with net debt to EBITDA at 3.45. When we switch over and look at the enterprise to sales, we see a ratio of 560.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.85.
Conclusion
In conclusion, Alto Neuroscience Inc. (ANRO) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
